×
Back to Agenda
Session 2: Lessons Learned and Best Practices for Decentralized Clinical Trials: Can We Plan and Execute More Patient-Friendly Clinical Trials?
Session Chair(s)
Megan Doyle, JD, MPH
Associate Vice President, Assistant General Counsel - Diagnostics, Eli Lilly and Company, United States
This session will focus on what we’ve learned thus far in trying to implement decentralized techniques in clinical trials. Specifically, speakers will share lessons learned and best practices observed to date. Additionally, based on these lessons learned, we will discuss remaining challenges and paths forward for addressing those challenges.
Learning Objective : At the conclusion of this session, participants should be able to:- Articulate best practices in planning and executing decentralized trials
- Understand some lessons learned related to using decentralized techniques in clinical trials to date
- Assess the challenges that remain for broad scale decentralized trial adoption
Speaker(s)
Scott Askin, MSC
Global Program Regulatory Director, Novartis Pharma AG, Switzerland
Abba Elizabeth Theogaraj, PHD
Regulatory Senior Group Director, Roche, Switzerland
Reem Yunis, PHD
Vice President, Digital Transformation Strategy, Medable, United States
Sarah Krug, MS
Executive Director, CANCER101, United States
Have an account?